FMI
Foundation Medicine, Inc.
A maker of genomic tests that help doctors personalize cancer treatment, Foundation Medicine analyzes hundreds of cancer-related genes in a single tumor sample to find the mutations driving a patient's disease. Its flagship test, FoundationOne, was named to signal a "one-stop" comprehensive look at a tumor's genetics. Founded in 2010 by scientists from the Broad Institute of MIT and Harvard, the company chose its name to reflect a mission to build a new "foundation" for cancer care, and it became part of the Roche Group in 2018.
CUSIP: 350465100HealthcareUS1 holder
Recent Activity
2018Q3
1 sell
-19.7K shares
ARK InvestEXIT
-19.7K shares
2018Q2
1 sell
-67.7K shares(-77.4%)
ARK InvestTRIM
-67.7K shares(-77.4%)
2018Q1
1 sell
-171.3K shares(-66.2%)
ARK InvestTRIM
-171.3K shares(-66.2%)
Loading more activity...